Categories: HealthcareNews

ResMed to Report First Quarter Fiscal 2023 Earnings on October 27, 2022

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) — ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2023 on Thursday, October 27, 2022, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this webcast.

Earnings webcast details:

  Location:  http://investor.resmed.com
  Date:  Thursday, October 27, 2022
  Time:  1:30 p.m. PDT / 4:30 p.m. EDT
  International: London, Thursday, October 27, 9:30 p.m. BST
      Sydney, Friday, October 28, 7:30 a.m. AEDT

Please note that ResMed does not use outside phone lines to access the earnings call.

A replay of the earnings webcast will be accessible on ResMed’s website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately two hours after the webcast and will be accessible from October 27 until November 10 at:

  U.S.: +1 877.660.6853
  International: +1 201.612.7415
  Conference ID: 13733726

About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

For investors
Amy Wakeham
+1 858.836.5000
investorrelations@resmed.com
For media
Jayme Rubenstein
+1 858.836.6798
news@resmed.com

Staff

Recent Posts

Lyra Growth Partners Inc. Announces Sale of Common Shares of BuildDirect.com Technologies Inc.

Vancouver, British Columbia--(Newsfile Corp. - May 28, 2025) - Lyra Growth Partners Inc. ("Lyra") announces…

3 hours ago

SCAN Named the Winner of the 2025 Hearst Health Prize

$100,000 Hearst Health Prize recognizes innovative initiatives using data science to make a health impact…

5 hours ago

Nanalysis Announces First Quarter 2025 Results

Delivers Another Quarter of Positive Adjusted EBITDA & Operating Cash Flow CALGARY, AB, May 28,…

5 hours ago

Veeva Announces Fiscal 2026 First Quarter Results

Total Revenues of $759.0M, up 17% Year Over YearSubscription Services Revenues of $634.8M, up 19%…

5 hours ago

Staffency, a TotalMed Company, Announces Merger with SimpliFi to Enhance Workforce Solutions

APPLETON, Wis., May 28, 2025 /PRNewswire/ -- Staffency, a premier workforce solutions provider and division…

5 hours ago

World-Renowned Mold Illness Expert Dr. Scott McMahon Joins MoldCo as Medical Director

Together, They Aim to Solve One of America's Most Overlooked Health Crisis: Mold Toxicity LOS…

5 hours ago